Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DHPS | P49366 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18908175 | 0.89 | KCNH2 (0.38) | KCNH2TMEM97SIGMAR1KDM4EHTR2C | |
| SCHEMBL18909761 | 0.88 | USP2 (0.39) | KCNH2TAS1R3TAS1R1KDM4EHTR2C | |
| SCHEMBL18821185 | 0.87 | KCNH2 (0.38) | KCNH2TMEM97SIGMAR1KDM4EHTR2C | |
| SCHEMBL18909756 | 0.86 | KDM4E (0.38) | KCNH2TAS1R3TAS1R1KDM4EHTR2C | |
| SCHEMBL18907016 | 0.85 | TAS1R3 (0.39) | TAS1R3TAS1R1KDM4EHTR2CHTR2A | |
| SCHEMBL18964830 | 0.84 | KCNH2 (0.39) | KCNH2TMEM97SIGMAR1TAS1R3TAS1R1 | |
| SCHEMBL21231886 | 0.84 | TAS1R3 (0.39) | TAS1R3TAS1R1KDM4E | |
| SCHEMBL18909763 | 0.83 | TAS1R3 (0.39) | TAS1R3TAS1R1KDM4EHTR2CHTR2A | |
| SCHEMBL18909753 | 0.83 | TAS1R3 (0.39) | TAS1R3TAS1R1KDM4EHTR2CHTR2A | |
| SCHEMBL21231883 | 0.80 | PGR (0.40) | TAS1R3TAS1R1KDM4EHTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| WO-2017091602-A1 | ESTER ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017091600-A1 | PYRAZOLE ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT1 | KCNH2 4441/4885TMEM97 4016/4885SIGMAR1 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.